Abstract
The discovery of gamma-hydroxybutyrate (GHB) over 40 years ago led to its immediate use as a general anesthetic agent. Subsequent research demonstrated that GHB is an endogenous compound in the mammalian brain and current research suggests that GHB is a probable neurotransmitter. In the United States, reports of anabolic effects lead to its misuse among body builders during the 1980s while the intoxicating properties of the drug lead to its popularization as a substance of abuse during the 1990s. GHB became associated with reports of drug-facilitated sexual assault and cases of physical dependence and withdrawal. Efforts to ban GHB caused increased use of GHB analogues and pro-drugs. Against this backdrop, GHB was being developed for the treatment of narcolepsy, leading to the approval of Xyrem® (sodium oxybate) oral solution in 2002 for the treatment of cataplexy in patients with narcolepsy. A risk management program permits the safe handling and distribution of the approved product, minimizes the risk for diversion, provides professional and patient education about the risks and benefits of sodium oxybate, and includes physician and patient registries. Post-marketing surveillance indicates sodium oxybate has an acceptable safety profile and presents minimal risk for the development of physical dependence.
Keywords: GHB, sodium oxybate, gamma-hydroxybutyrate, risk management, drug safety
Current Drug Safety
Title: The Clinical Development of γ-Hydroxybutyrate (GHB)
Volume: 1 Issue: 1
Author(s): Gregory P. Wedin, Carl S. Hornfeldt and Lisa M. Ylitalo
Affiliation:
Keywords: GHB, sodium oxybate, gamma-hydroxybutyrate, risk management, drug safety
Abstract: The discovery of gamma-hydroxybutyrate (GHB) over 40 years ago led to its immediate use as a general anesthetic agent. Subsequent research demonstrated that GHB is an endogenous compound in the mammalian brain and current research suggests that GHB is a probable neurotransmitter. In the United States, reports of anabolic effects lead to its misuse among body builders during the 1980s while the intoxicating properties of the drug lead to its popularization as a substance of abuse during the 1990s. GHB became associated with reports of drug-facilitated sexual assault and cases of physical dependence and withdrawal. Efforts to ban GHB caused increased use of GHB analogues and pro-drugs. Against this backdrop, GHB was being developed for the treatment of narcolepsy, leading to the approval of Xyrem® (sodium oxybate) oral solution in 2002 for the treatment of cataplexy in patients with narcolepsy. A risk management program permits the safe handling and distribution of the approved product, minimizes the risk for diversion, provides professional and patient education about the risks and benefits of sodium oxybate, and includes physician and patient registries. Post-marketing surveillance indicates sodium oxybate has an acceptable safety profile and presents minimal risk for the development of physical dependence.
Export Options
About this article
Cite this article as:
Wedin P. Gregory, Hornfeldt S. Carl and Ylitalo M. Lisa, The Clinical Development of γ-Hydroxybutyrate (GHB), Current Drug Safety 2006; 1 (1) . https://dx.doi.org/10.2174/157488606775252647
DOI https://dx.doi.org/10.2174/157488606775252647 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Urinary Steroids Measured by Modern Separation Techniques and Applied as Biomarkers in Stress Studies
Current Pharmaceutical Analysis Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design Aberrant DNA Methylation Pattern may Enhance Susceptibility to Migraine: A Novel Perspective
CNS & Neurological Disorders - Drug Targets Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters The Impact of Hypertension in Hemodialysis Patients
Current Hypertension Reviews Evaluation of Tophaceous Gout by FDG-PET/CT and Bone Scan
Current Molecular Imaging (Discontinued) Capsule Endoscopy in Crohn’s Disease
Current Drug Targets Antimicrobial Sensitivity Pattern of Bacterial Pathogens in Urinary Tract Infections in South Delhi, India
Reviews on Recent Clinical Trials Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Regulators of G Protein Signaling: Potential Drug Targets for Controlling Cardiovascular and Immune Function
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis
Current Neuropharmacology Management of the Low Cardiac Output Syndrome Following Surgery for Congenital Heart Disease
Current Cardiology Reviews Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Genes, Environment, Intermediate Phenotypes, and the Pathogenesis of Diabetic Nephropathy
Current Pharmacogenomics Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Biological Active Peptides from Marine Sources Related to Gut Hormones
Current Protein & Peptide Science